Fig. 12
From: The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy
Copyright 2019, American Chemical Society publishing group
A Schematic of nanoactivtors inducing autophagy for cross-presentation and priming T cells. B Nanoactivator-mediated autophagic flux detection. i: Co-localization organelles ER and Golgi complex with NP-B-OVA-Cy5 after incubation for 1.5 h (upper panel) and 3 h (lower panel); white dashed boxes indicate the co-localization signals; blue, ER-tracker; green, Golgi complex; red, NP-B-OVA nanoparticles, n = 3. ii: Confocal images of DC2.4 cells 2 h post NP-B-OVA-Cy5 incubation and stained with indicated organelles probes. Scale bar, 5 μm, n = 3. C in vivo antitumor efficacy of nanoactivator. i: Tumor volume changes of B16-F10-OVA bearing mice with indicated treatments, n = 6***p < 0.001; one-way ANOVA for indicated comparison. ii: Percentages of cross-presentation DCs in lymph node 7 d after indicated treatments. iii: Percentages of antigen-specific CD8 + T cells isolated from the spleen 7 d after indicated treatments.